Navigation Links
Long-term Use of Herceptin Does Not Increase Heart Failure in Patients

CHICAGO, A five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago states that the risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time.

The research team developed a prediction model based on these findings. The model will help oncologists to assess the risk of heart failure in individual breast cancer patients before treatment with Herceptin and chemotherapy. These findings, to be announced at the Womens Cancers press briefing at the meeting, will be published in Abstract LBA513 in the ASCO proceedings.

The information we obtained from this study is essential to understanding womens risks for congestive heart failure associated with adding Herceptin to combination chemotherapy for breast cancer treatment, said Priya Rastogi, M.D., study presenter and assistant professor, University of Pittsburgh School of Medicine and assistant director of medical affairs, NSABP. Were encouraged that we found no increase in heart failure risks long-term and now are able to use this knowledge to individualize womens treatment based on their specific cardiac risk factors.

The study assessed cardiac side effects in 1,850 women with HER-2 positive breast cancer those who have abnormally high levels of the HER2/neu protein for five years. Study participants were initially randomized to receive four cycles of a standard combination chemotherapy regimen, doxorubicin and cyclophosphamide followed by paclitaxel, or doxorubicin and cyclophosphamide followed by paclitaxel and Herceptin.

The incidence of congestive heart failure was compared between the two groups. Initial three-year follow-up results reported that although Herceptin provides a clear and notable benefit to women with HER-2 po sitive breast cancer, it also causes an increased risk for congestive heart failure a 4.1 percent incidence of congestive health failure was reported in the Herceptin and chemotherapy group compared to a 0.8 percent increase in the control group.

The current study found that after five years follow-up, the incidence of congestive heart failure was virtually unchanged 3.8 percent of patients who received Herceptin and chemotherapy experienced congestive heart failure, compared to 0.9 percent of patients in the control group. Congestive heart failure was measured using a Multiple Gated Acquisition scan, or a MUGA scan a noninvasive tool that produces a moving image of the beating heart to determine the health of the cardiac ventricles.

The research team also identified possible risk factors for breast cancer patients more likely to develop congestive heart failure from adding Herceptin to combination chemotherapy. They developed a prediction model based on these factors, including hypertension, age and baseline cardiac function.

It is our hope that this model will help to individualize care for women in terms of choice of Herceptin-containing treatment regimens based on their personal risk and benefits, said Dr. Rastogi.


'"/>




Related medicine news :

1. Long-term use of calcium supplements to prevent colon cancer
2. Long-term Care Should Be A Planned Affair
3. Long-term Ibuprofen Therapy After Brain Injury Deteriorate Cognitive Abilities
4. Global AIDS Conference Calls for Long-term Strategies
5. Long-term Use of Stomach Drugs may Weaken Bones
6. Asthma Sufferers Favor Quick Relief Over Long-term Control
7. Long-term Marijuana Smoking Leads to Respiratory Complaints
8. Tamoxifen Yields Long-term Reduction in Breast Cancer Risk
9. Angioplasty Reduces Long-term Cardiac Risk in Heart Patients With silent Ischemia
10. Functional Foods Must Be Monitored to Assess Their Long-term Safety and Effectiveness
11. Cancer Drug Induces HDAC Inhibitor and Enhance Long-term Memory
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology: